Novo Nordisk and Gilead expand partnership
In a new phase IIb study, Novo Nordisk and Gilead plan to test a combination of three different drug treatments against nonalcoholic steatohepatitis (NASH), thereby extending the two companies' collaboration deal signed in 2019.
BY ELIZABETH MØNSTED JOHANSEN, TRANSLATED BY DANIEL FRANK CHRISTENSEN
Novo Nordisk and Gilead now declare themselves ready to expand their partnership agreement to tackle nonalcoholic steatohepatitis (NASH).
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
